USC. Recombinant ferri-piscibactine receptor protein and its application against pasteurellosis

USC. Recombinant bacterial protein as a fish vaccine[line_break]P 201531020

Project Description

The USC research group is the holder of patent 201531020 aimed at obtaining a recombinant ferri-piscibactine receptor protein in addition to its application for the production of an immunogenic composition against pasteurellosis.

Although there are some commercial vaccines based on inactivated whole bacterial cells, they do not offer complete and long-lasting protection against the disease, mainly in some cultivated fish species of high commercial value such as sole.

The USC research group describes a new vaccine based on the use of a recombinant protein obtained from an outer membrane protein (ferri-piscibactine receptor) of Photobacterium damselae subsp piscicida, the causal agent of pasteurellosis. The protein was cloned, expressed and purified from an Escherichia coli strain.

You can consult the patent description sheet.

Description of the Area of Activity / Technology

Prevention of pasteurellosis in juvenile sole can be achieved by using this recombinant protein. The protein can be easily obtained from an E. coli culture without the need to grow the bacterial pathogen. The toxic and inflammatory effects on vaccinated fish of current vaccines can be avoided in the absence of environmental risks.

If this offer is of interest to you or you need more information about it, please contact us. This offer can take the form of a «Partnership Agreement» to adapt this technology to your areas of research, or a «License Agreement» to use this patent directly.